SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is trending due to expanded commercial coverage for its fibromyalgia drug, TONMYA, reaching 52 million lives, while the community intensely debates the balance between improving commercial metrics and ongoing concerns regarding potential stock dilution. Investors are actively tracking prescription script growth as a key indicator of commercial adoption.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is experiencing a surge in trading activity driven by the massive expansion of its project pipeline and manufacturing capacity to support the increasing power demands of AI data centers. The community is actively debating the stock's potential as an infrastructure play while remaining highly focused on the company's ability to convert its growing proposal backlog into signed, profitable contracts.

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in Brisbane, CA.

Nurix Therapeutics Inc

Nurix Therapeutics is surging as the community celebrates a major global collaboration with Roche to co-develop the oral BTK degrader bexobrutideg, a deal providing significant upfront cash and long-term milestone potential. Investors are actively discussing the de-risked financial outlook and the stock's massive market opportunity, with many viewing the partnership as strong external validation of the companys drug degradation platform.

Corning, Inc. engages in the provision of glass for notebook computers, flat panel desktop monitors, display televisions, and other information display applications, carrier network and enterprise network products for the telecommunications industry, ceramic substrates for gasoline and diesel engines in automotive and heavy-duty vehicle markets, laboratory products for the scientific community and polymer products for biotechnology applications, optical materials for the semiconductor industry and the scientific community, and polycrystalline silicon products and other technologies. It operates through the following segments: Optical Communications, Display, Specialty Materials, Automotive, and Life Sciences. The Optical Communications segment is classified into two main product groupings: carrier and enterprise network. The carrier network group consists of products and solutions for optical-based communications infrastructure for services such as video, data, and voice communications. The enterprise network group consists primarily of optical-based communication networks sold to businesses, governments, and individuals for their own use. The Display Technologies segment manufactures glass substrates for flat panel displays, including organic light-emitting diodes and liquid crystal displays that are used primarily in televisions, notebook computers, desktop monitors, tablets, and handheld devices. The Specialty Materials segment is involved in the manufacture of products that provide material formulations for glass, glass ceramics and crystals, and precision metrology instruments and software. The Automotive segment manufactures ceramic substrates and filter products for emissions control in mobile applications around the world as well as technical glass and optic products and solutions for the interior and exterior of vehicles. The Life Sciences segment develops, manufactures, and supplies laboratory products. The company was founded by Amory Houghton Sr. in 1851 and is headquartered in Corning, NY.

Corning, Inc.

Corning, Inc. is surging following a landmark multi-year partnership with Nvidia to significantly expand U.S. manufacturing capacity for optical connectivity and fiber-optic infrastructure required for AI data centers. Investors and community members are actively discussing the stock's role as a critical 'picks and shovels' play, with many noting that the company's glass and fiber technologies are essential for the horizontal scaling of modern AI infrastructure.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as investors react to the company's multi-year agreement to provide AI compute infrastructure, a move that signals its transition toward becoming a significant independent cloud and AI player. The community is actively debating the stock's massive short interest and the strategic value of the Northern Data acquisition, with many focused on the long-term potential of Rumble's growing GPU footprint despite recent volatility.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is currently generating significant market attention due to emerging reports that tech giants Google and Nvidia are considering the company as a key backup manufacturer for AI chips to address supply chain constraints. The community is intensely debating these strategic partnerships and the potential for Intel's 18A process to play a larger role in AI infrastructure, with bulls highlighting the long-term foundry growth thesis while bears express skepticism regarding immediate execution.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly shares are surging as positive Phase 3 clinical trial results for its triple-agonist obesity drug, retatrutide, confirm best-in-class efficacy for weight loss and cardiometabolic health. The community is actively discussing the drug's potential to set a new benchmark in the weight-loss market, even as investors weigh the balance between record-breaking trial data and the long-term competitive dynamics within the GLP-1 sector.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

Occidental Petroleum is drawing significant investor attention as ongoing geopolitical tensions in the Middle East and the volatility of the Strait of Hormuz keep oil prices elevated and speculative interest in energy sector volatility high. The community is actively debating the stock's potential for a breakout, with many investors weighing the impact of continued production discipline and potential supply shocks against the uncertainty surrounding government-led peace headlines.

The Campbell's Co. engages in the business of manufacturing and marketing food and beverage products. It operates under the Meals and Beverages, and Snacks segments. The Meals and Beverages segment includes soup, meals, and beverage products in retail and foodservice. The Snacks segment offers cookies, crackers, bakery, and frozen products. The company was founded by Joseph Campbell and Abraham Anderson in 1869 and is headquartered in Camden, NJ.

Campbells Co (The)

Campbell Soup Co.

Campbell Soup is seeing increased volatility as investors weigh lingering concerns over sector-wide consumer demand and tariff-related margin pressures against the company's defensive appeal and high dividend yield. Market sentiment remains split, with some traders actively betting on a potential rebound driven by institutional accumulation, while others express caution regarding elevated debt levels and broader headwinds facing the packaged food industry.

EHang Holdings Ltd. engages in the provision of aerial vehicle technology platform company. It also provides unmanned aerial vehicle (UAV) systems and solutions: air mobility (including human transportation and logistics), smart city management, and aerial media solutions. The firm operates through the following geographical segments: P.R.C., West Asia, East Asia, South America, Europe, and Other. The company was founded by Huazhi Hu and Yifang Derrick Xiong in December 2014 and is headquartered in Guangzhou, China.

EHang Holdings Ltd - ADR

EHang Holdings

EHang is trending due to anticipation surrounding its upcoming earnings report and growing momentum in the low-altitude economy sector, driven by recent commercial flight milestones in global markets like Thailand and Qatar. Community discussion remains polarized, with many investors highlighting the stock's significant long-term potential as a certified first-mover, while others express frustration over stagnant price action and regulatory delivery timelines.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bicara Therapeutics (BCAX) Expected to Announce Quarterly Earnings on Tuesday

Bicara Therapeutics (NASDAQ:BCAX) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at...

Bicara Therapeutics Chief Medical Officer Sells 5,500 Shares for $126,000

Key PointsCMO David Raben sold 5,500 shares of common stock for a transaction value of $126,000 on April 27...

Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) Insider Sells 5,500 Shares of Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) insider David Raben sold 5,500 shares of the stock in a transaction dated Monday, April 27th. The stock was sold at an average price of...

Ivan Hyep Sells 9,200 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CFO Ivan Hyep sold 9,200 shares of the company's stock in a transaction that occurred on Tuesday, April 21st. The shares were sold at an...

Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CFO Sells 9,200 Shares of Stock

Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CEO Sells 15,000 Shares of Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CEO Claire Mazumdar sold 15,000 shares of the business's stock in a transaction on Monday, April 20th. The stock was sold at an average price...

Bicara Therapeutics (NASDAQ:BCAX) CEO Claire Mazumdar Sells 15,000 Shares

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CEO Claire Mazumdar sold 15,000 shares of the business's stock in a transaction dated Monday, April 20th. The shares were sold at an average...

Ryan Cohlhepp Sells 12,500 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) COO Ryan Cohlhepp sold 12,500 shares of the business's stock in a transaction dated Wednesday, April 15th. The shares were sold at an average...

Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) COO Sells 12,500 Shares of Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) COO Ryan Cohlhepp sold 12,500 shares of the firm's stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $23.01, for a total value of $287,625.00. Following the sale, the chief operating officer...

Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the twelve brokerages that are currently covering the stock, Marketbeat reports...

Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company’s bi-functional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Its products include BCA101, a first-in-class EGFR/TGF-ß-trap bifunctional antibody in clinical development for multiple tumor types. The company was founded on December 12, 2018 and is headquartered in Boston, MA.

BCAXBicara Therapeutics

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BCAX News